Quantum BioPharma Ltd. was featured in CTV News' W5 program, which aired Part Three of an investigative series examining the company's allegations of stock spoofing tied to its USD $700 million lawsuit against CIBC and RBC. The episodes detail rising market-manipulation cases in Canada and highlight Quantum's call for accountability. CEO Zeeshan Saeed reaffirmed the company's commitment to defending shareholders and advancing MS research through its lead compound, Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models. Co-Executive Chair Anthony Durkacz has offered up to USD $7 million for information leading to a final judgment or settlement in related litigation.
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company focuses on the research and development of Lucid-MS, targeting the underlying mechanism of multiple sclerosis. The company also invented unbuzzd(TM) and spun out its OTC version to Unbuzzd Wellness Inc., retaining ownership of 20.11% of the company as of March 31, 2025. The agreement includes royalty payments of 7% of sales from unbuzzd(TM) until payments to Quantum BioPharma total $250 million, after which the royalty drops to 3% in perpetuity. Quantum BioPharma retains 100% of the rights to develop similar products for pharmaceutical and medical uses.
This development matters because it represents a convergence of financial market integrity concerns and potentially groundbreaking medical research. The allegations of stock spoofing against major Canadian financial institutions highlight systemic issues in market manipulation that can undermine investor confidence and distort capital markets. Quantum BioPharma's lawsuit seeks accountability for practices that allegedly harmed shareholders, while the company simultaneously advances research that could transform treatment for multiple sclerosis patients. The implications extend beyond this single company to broader questions about regulatory oversight in financial markets and the funding environment for innovative biopharmaceutical research.
Additional information about the company is available in its newsroom at https://ibn.fm/QNTM. The press release containing this information was disseminated through InvestorWire, a specialized communications platform that is one of 70+ brands within the Dynamic Brand Portfolio at IBN, providing wire-grade press release syndication and corporate communications solutions. Full terms of use and disclaimers are available on the InvestorWire website at https://www.InvestorWire.com/Disclaimer.
